NCT00345878View on ClinicalTrials.gov

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

271

Participants

Timeline

Start Date

September 25, 2006

Primary Completion Date

December 21, 2007

Study Completion Date

December 21, 2007

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

Placebo

Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

BIOLOGICAL

HPV-16/18 L1 VLP AS04 (Cervarix TM)

Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

Trial Locations (2)

50603

GSK Investigational Site, Kuala Lumpur

62250

GSK Investigational Site, Kerajaan Persekutuan Putrajaya

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00345878 - Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years | Biotech Hunter | Biotech Hunter